ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2026
Rapid Extensively Drug-Resistant (XDR) TB Diagnosis: An In-House DNA Biochip for Drug Resistance Detection and Mutation Profiling of
Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid Extensively Drug-Resistant (XDR) TB Diagnosis: An In-House DNA Biochip for Drug Resistance Detection and Mutation Profiling ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Methods: The biochip allowed the detection of 20 drug resistance-determining mutations in the Results: Out of 59 culture sensitive isolates, 53 were sensitive to all drugs by biochip, while 6 isolates showed different mutations. The biochip showed high concordance with culture DST. The diagnostic sensitivity of the biochip assay for all the drugs ranged from 75% to 100%. The specificities of the biochip for all the 7 drugs were over 97%. The developed biochip demonstrated analytical sensitivity of 10 Conclusions: The biochip enables simultaneous analysis of multiple resistance-associated mutation in a single assay providing a powerful tool for early detection, personalized therapy, and effective containment of both MDR and XDR-TB. The biochip is useful for clinical microbiology studies and surveillance programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.